Scholar Rock updates global regulatory progress for apitegromab

Scholar Rock has given investors an update on apitegromab's path through US, European, and Japanese regulators, and the timeline shows the drug is closer to reaching a different group of patients than anyone taking a GLP-1 medication for weight loss.

The company had set a US regulatory action date of September 30, 2026, after a 2025 complete response letter tied to a third-party manufacturing facility that handles the drug's fill-finish process, not to apitegromab itself ^[1]. Following a resubmission and a change of facility, the FDA moved ahead of that date: on September 11, 2026, the agency approved apitegromab, sold as ISEMBYLD, for spinal muscular atrophy (SMA) in adults and children age two and older who are already receiving a separate SMA-targeted treatment ^[2].

The approval rested on the Phase 3 SAPPHIRE trial, which found a 2.2-point improvement on the Hammersmith Functional Motor Scale-Expanded compared with placebo after one year, in a main efficacy population of 103 patients ages 2 to 12 (nominal p=0.0121) ^[2]. About 34.2 percent of patients on apitegromab gained at least three points on that scale, compared with 13.5 percent of patients on placebo ^[2]. Scholar Rock's safety database across all apitegromab studies includes more than 500 people, some treated for over seven years, with the most common side effects being upper respiratory infections, vomiting, cough, headache, and other viral illnesses; fractures occurred in 9 percent of treated patients versus 2 percent on placebo ^[2].

None of that SMA approval directly changes anything for people taking semaglutide or tirzepatide for weight loss. Apitegromab's separate link to obesity treatment comes from the Phase 2 EMBRAZE trial, which paired the drug with tirzepatide in 102 participants over 24 weeks and found 54.9 percent greater relative lean-mass retention than tirzepatide combined with a placebo ^[1]. Apitegromab works by targeting pro-myostatin and the latent myostatin complex, a step that blocks activation of a protein that normally limits muscle growth ^[1].

Why it matters for patients

Muscle loss during rapid weight loss on GLP-1 drugs is a recognized concern, and apitegromab is one of several experimental drugs being studied as an add-on meant to preserve lean mass. But the SMA approval and the obesity research sit on two separate regulatory tracks. Apitegromab now has a marketed use, ISEMBYLD, for SMA, backed by an established safety record in that population ^[2]. Its use alongside a GLP-1 drug for weight loss has been tested only in a 102-person, 24-week study, and no company has filed for that combined use with regulators ^[1].

Patients currently taking a GLP-1 medication should not expect any near-term change tied to this update. Apitegromab is not approved, and is not under active regulatory review, for use alongside semaglutide or tirzepatide. It is one of at least four molecules, alongside bimagrumab, trevogrumab (with or without garetosmab), and taldefgrobep alfa, being studied for the same purpose, and none of them has completed the trials that regulators would require before such a combination could be prescribed ^[1].

What happens next

Scholar Rock's original US action date for apitegromab was September 30, 2026, but the FDA approved the SMA use on September 11, 2026, ahead of that date ^[2]. The company is also pursuing approval in Europe and Japan, though the sources do not give specific dates for those reviews ^[1]. On the obesity side, EMBRAZE was a 24-week study in 102 participants, and the sources do not indicate that a larger or longer trial testing apitegromab together with a GLP-1 drug has yet begun ^[1].